Literature DB >> 10589360

Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis.

P J Mroczkowski1, M E Weinblatt, J M Kremer.   

Abstract

An open-label, one-year study was conducted to evaluate the safety and clinical response to leflunomide and methotrexate combination therapy for rheumatoid arthritis. Study results revealed tolerable safety, no significant pharmacokinetic interactions between methotrexate and leflunomide, and suggested improved clinical response with combination therapy.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10589360

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  3 in total

1.  Leflunomide: new antirheumatic drug. Effect on pregnancy outcomes.

Authors:  E Kozer; M E Moretti; G Koren
Journal:  Can Fam Physician       Date:  2001-04       Impact factor: 3.275

2.  Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use : open-label, prospective study.

Authors:  Minh Nguyen; Marmar Kabir; Philippe Ravaud
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 3.  Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Judith Trudeau; Veerapong Phumethum; Claire Bombardier
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.